CTMX — CytomX Therapeutics, Inc.

Summary of CytomX Therapeutics Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of March 31, 2026, CytomX reported $346.7 million in cash, cash equivalents, and investments, a significant increase from $137.1 million at the end of 2025.
• Revenue: Total revenue for Q1 2026 was $10.3 million, down from $50.9 million in Q1 2025, primarily due to the completion of collaboration obligations with Bristol Myers Squibb and Amgen.
• Operating Expenses: Operating expenses rose to $29.8 million from $28.3 million year-over-year. Research and development (R&D) expenses were $19.2 million, reflecting increased manufacturing activities for Varseta-M.

2. Strategic Updates and Business Highlights

• Varseta-M Development: CytomX is advancing Varseta-M, a first-in-class EpCAM-targeting antibody drug conjugate, in late-line colorectal cancer (CRC). Recent Phase I data showed an overall response rate of 20%-32% and a median progression-free survival (PFS) of approximately 7 months.
• Regulatory Strategy: The company aims to initiate a registrational study for Varseta-M in late-line CRC in the first half of 2027, with ongoing dose optimization and a focus on patient management strategies to mitigate adverse events.
• Combination Studies: CytomX is exploring combinations of Varseta-M with bevacizumab and chemotherapy to expand its application in earlier lines of CRC treatment.
• CX-801 Program: The masked interferon alpha-2b program for advanced melanoma is progressing well, with initial data expected by the end of 2026.

3. Forward Guidance and Outlook

• Clinical Updates: CytomX plans to provide a comprehensive update on Varseta-M’s Phase I data, including safety and efficacy, in the second half of 2026. They expect to share overall survival data from earlier phases as well.
• Cash Runway: The company projects a cash runway extending to at least the second half of 2028, allowing for continued investment in Varseta-M and other strategic initiatives.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The significant drop in revenue compared to the previous year raises concerns about the sustainability of income from collaborations.
• Adverse Events: High-grade diarrhea remains a principal adverse event for Varseta-M, although management strategies are being optimized to reduce its incidence. The company aims to maintain a Grade 3 diarrhea rate between 10%-20%.
• Competitive Landscape: The oncology market is competitive, particularly for antibody-drug conjugates, raising concerns about market share and differentiation from other products in development.

5. Notable Q&A Insights

• Clinical Data Expectations: The second half of 2026 will include a detailed update on the dose optimization cohort, including PFS and potentially early overall survival data.
• Combination Therapy Plans: The company plans to evaluate Varseta-M in combination with chemotherapy and bevacizumab, with no gating issues anticipated for starting these studies.
• Regulatory Engagement: Ongoing interactions with the FDA are expected to be informed by the data from the optimization cohorts, which will be crucial for finalizing the pivotal trial design.

Overall, CytomX is positioned for significant developments in 2026, particularly with Varseta-M, while navigating challenges related to revenue and competitive pressures in the oncology market.